中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2009年
35期
2486-2489
,共4页
杨浩贤%侯雪%林鹏%戎铁华%杨弘%傅剑华
楊浩賢%侯雪%林鵬%戎鐵華%楊弘%傅劍華
양호현%후설%림붕%융철화%양홍%부검화
癌%非小细胞肺%肿瘤转移%预后
癌%非小細胞肺%腫瘤轉移%預後
암%비소세포폐%종류전이%예후
Carcinoma%non-small-cell lung%lntralobar metastasis%Prognosis
目的 分析同肺叶内转移的N0-1M0非小细胞肺癌的预后,探讨将叶内转移的非小细胞肺癌的T4分期进行下调的合理性.方法 通过回顾性分析,评估2001年1月至2007年9月中山大学肿瘤防治中心胸外科收治的手术治疗的同肺叶内转移的非小细胞肺癌患者的临床资料.入组患者的术后病理分期为N0-1M0期,评价这些患者的预后情况.统计分析用SPSS 10.0完成,生存分析用Kaplan-Meier法.结果 共有46例患者符合入组条件,纳入生存分析.总的5年生存率为29.2%,中位生存期为53.0个月.腺鳞癌的中位生存期为24个月,而其他病理类型的中位生存期为48个月,差异有统计学意义(P=0.003).全肺切除者中位生存期为24个月,非全肺切除者中位生存期为60个月,差异有统计学意义(P=0.023).结论 将伴有同肺叶内转移的非小细胞肺癌的T4分期进行下调是合理的;同肺叶内转移的N0-1M0的非小细胞肺癌是有手术指征的,但全肺切除需要慎重考虑.腺鳞癌患者的预后较差,但需要更大样本的研究来证实.
目的 分析同肺葉內轉移的N0-1M0非小細胞肺癌的預後,探討將葉內轉移的非小細胞肺癌的T4分期進行下調的閤理性.方法 通過迴顧性分析,評估2001年1月至2007年9月中山大學腫瘤防治中心胸外科收治的手術治療的同肺葉內轉移的非小細胞肺癌患者的臨床資料.入組患者的術後病理分期為N0-1M0期,評價這些患者的預後情況.統計分析用SPSS 10.0完成,生存分析用Kaplan-Meier法.結果 共有46例患者符閤入組條件,納入生存分析.總的5年生存率為29.2%,中位生存期為53.0箇月.腺鱗癌的中位生存期為24箇月,而其他病理類型的中位生存期為48箇月,差異有統計學意義(P=0.003).全肺切除者中位生存期為24箇月,非全肺切除者中位生存期為60箇月,差異有統計學意義(P=0.023).結論 將伴有同肺葉內轉移的非小細胞肺癌的T4分期進行下調是閤理的;同肺葉內轉移的N0-1M0的非小細胞肺癌是有手術指徵的,但全肺切除需要慎重攷慮.腺鱗癌患者的預後較差,但需要更大樣本的研究來證實.
목적 분석동폐협내전이적N0-1M0비소세포폐암적예후,탐토장협내전이적비소세포폐암적T4분기진행하조적합이성.방법 통과회고성분석,평고2001년1월지2007년9월중산대학종류방치중심흉외과수치적수술치료적동폐협내전이적비소세포폐암환자적림상자료.입조환자적술후병리분기위N0-1M0기,평개저사환자적예후정황.통계분석용SPSS 10.0완성,생존분석용Kaplan-Meier법.결과 공유46례환자부합입조조건,납입생존분석.총적5년생존솔위29.2%,중위생존기위53.0개월.선린암적중위생존기위24개월,이기타병리류형적중위생존기위48개월,차이유통계학의의(P=0.003).전폐절제자중위생존기위24개월,비전폐절제자중위생존기위60개월,차이유통계학의의(P=0.023).결론 장반유동폐협내전이적비소세포폐암적T4분기진행하조시합리적;동폐협내전이적N0-1M0적비소세포폐암시유수술지정적,단전폐절제수요신중고필.선린암환자적예후교차,단수요경대양본적연구래증실.
Objective To assess whether it is reasonable to downgrade intralobar metastatic non-small cell lung cancer from T4 disease through a prognostic analysis of N0-1M0 disease. Methods A retrospective analysis was conducted to assess the survival of patients with intralobar metastatic non-small cell lung cancer with pathological N0-1M0 disease. The Kaplan-Meier method was used to calculate the patient survival. Results Forty-six patients were included. The overall 5-year survival rate was 29.2% with a median survival of 53.0 months. The median survival was 24.0 months for patients with adenosquamous carcinoma; while for patients with other pathologic types, the median survival was 48 months. Adenosquamous carcinoma had a shorter survival time than other pathologic types (P = 0.003). The median survival time was 60.0 months for patients undergoing non-pneumonectomy resection and 24 months for patients undergoing pneumonectomy (P = 0.023). Conclusion It is reasonable to downgrade the T4 classification of non-small cell lung cancer with intralobar metastasis. However, pneumonectomy should be carried out with cautions. Adenosquamous carcinoma has a poor prognosis. Further study of a larger sample size is warranted.
